RT Journal Article
SR Electronic
T1 Immunogenicity and seroefficacy of pneumococcal conjugate vaccines – a systematic review and network meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.13.23284388
DO 10.1101/2023.01.13.23284388
A1 Feng, Shuo
A1 McLellan, Julie
A1 Pidduck, Nicola
A1 Roberts, Nia
A1 Higgins, Julian PT
A1 Choi, Yoon
A1 Izu, Alane
A1 Jit, Mark
A1 Madhi, Shabir A
A1 Mulholland, Kim
A1 Pollard, Andrew J
A1 Temple, Beth
A1 Voysey, Merryn
YR 2023
UL http://medrxiv.org/content/early/2023/01/17/2023.01.13.23284388.abstract
AB Background Vaccination of infants with pneumococcal conjugate vaccines (PCV) is recommended by the World Health Organisation. Evidence is mixed regarding the differences in immunogenicity and efficacy of the different pneumococcal vaccines.Methods In this systematic-review and network meta-analysis, we searched the Cochrane Library, Embase, Global Health, Medline, clinicaltrials.gov and trialsearch.who.int up to July 2022 (Protocol PROSPERO ID CRD42019124580). Studies were eligible if they presented data comparing the immunogenicity of either PCV7, PCV10 or PCV13 in head- to-head randomised trials for young children, and provided at least one time point after the primary vaccination series and/or one-month after a booster dose. Individual participant level data were requested from publication authors and/or the relevant vaccine manufacturer; aggregate data were extracted if individual data were unavailable. Outcomes included the geometric mean ratio (GMR) of serotype-specific IgG and relative risk (RR) of seroinfection. Seroinfection is defined as a rise in antibody between the primary vaccination series and the booster dose, as evidence of subclinical infection. We also estimated the relationship between the GMR one month after priming and the RR of seroinfection by the time of the booster dose.Findings In total 45 studies were eligible from 38 countries across six continents. 27 and 12 studies with data available were included in immunogenicity and seroefficacy analyses respectively. GMRs comparing PCV13 vs PCV10 favoured PCV13 for serotypes 4, 9V, and 23F at 1 month after primary vaccination series, with 1.14- to 1.54-fold significantly higher IgG responses with PCV13. Risk of seroinfection prior to the time of booster dose was lower for PCV13 for serotype 4, 6B, 9V, 18C and 23F than for PCV10. Two-fold higher antibody after primary vaccination was associated with 54% decrease in risk of seroinfection (RR 0.46, 95%CI 0.23-0.96).Conclusion Serotype-specific differences were found in immunogenicity and seroefficacy between PCV10 and PCV13. Higher immunogenicity of PCVs are associated with lower risk of subsequent infection. These findings could be further used to compare PCVs and optimise vaccination strategy.Funding This study is funded by the NIHR Health Technology Assessment programme (17/148/03).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is funded by the National Institute of Health Research (NIHR) Health Technology Assessment programme (17/148/03). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis publication is based on research using data from data contributor Pfizer that has been made available through Vivli, Inc and data contributor GSK that has been made available through clinicalstudydatarequest.com. Vivli and other third parties have not contributed to or approved, and are not in any way responsible for, the contents of this publication. Data were made available for a limited period of time to conduct these analyses. The authors do not have continuing access to the datasets.